0001708138-20-000118.txt : 20201231
0001708138-20-000118.hdr.sgml : 20201231
20201231173053
ACCESSION NUMBER: 0001708138-20-000118
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201230
FILED AS OF DATE: 20201231
DATE AS OF CHANGE: 20201231
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: YANCOPOULOS GEORGE
CENTRAL INDEX KEY: 0001226690
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 201429533
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-12-30
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001226690
YANCOPOULOS GEORGE
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
1
0
0
President and Chief Scientific
Common Stock
2020-12-30
4
M
0
240000
52.03
A
880938
D
Common Stock
2020-12-30
4
F
0
130714
483.25
D
750224
D
Common Stock
2020-12-30
4
M
0
158079
52.03
A
908303
D
Common Stock
2020-12-30
4
F
0
86096
483.25
D
822207
D
Common Stock
2020-07-27
5
G
0
57465
0.0
D
0
I
by 2018 GRAT
Common Stock
5821
I
By 401(k) Plan
Common Stock
376861
I
by 2019 GRAT
Non-Qualified Stock Option (right to buy)
52.03
2020-12-30
4
M
0
240000
0.0
D
2021-12-16
Common Stock
240000
158079
D
Non-Qualified Stock Option (right to buy)
52.03
2020-12-30
4
M
0
158079
0.0
D
2021-12-16
Common Stock
158079
0
D
With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 158,079 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.
/s/**George D. Yancopoulos
2020-12-31